The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Age 50 - 85
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Must have a study partner
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
60+
Diagnosis of Alzheimer's disease
Must have a study partner
It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.
You are eligible to participate if you meet the following criteria:
• Age ≥ 55; females must be post-menopausal
• DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)
• sMMSE ≤ 24
• Clinically significant agitation based on IPA definition
• Stable cognition-enhancing medication for at least 3 months prior to study enrolment
• Availability of a caregiver to accompany participant to study visits and to participate in the study
• Ability to speak English
Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.
Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.
Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.
Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.
Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.
Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.
Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.
Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.
Have not undergone any significant head trauma or surgery in the past 6 months.
Are not pregnant or planning to become pregnant during the duration of the study.
Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.
Ability to speak English and French
This Phase 2 study aims to study to evaluate the efficacy and safety of study treatment in paticipants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
Age 50 - 80
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Increasing evidence shows that listening to music from childhood and early adulthood can help recall meaningful events from the past. Importantly, people with dementia have shown to benefit from listening to personally meaningful music, suggesting that musical memory remains preserved. However, the underlying mechanisms by which music improves memory remains unclear.
My research addresses the impact of an autobiographically salient music listening program on memory and brain activity in mild cognitive impairment. Understanding how brainwave activity in this population may differ, will help elucidate mechanisms of music listening that lead to cognitive improvements, ultimately providing insight into musical memory preservation and how it can be leveraged.
Participants will undergo cognitive testing and measure brainwave activity via EEG, a non-invasive neuroimaging method. Participants will be provided an online link (or CD if they do not have wifi) to access their personalized music playlist and will be asked to listen for two weeks at home (20 mins/day, minimum 5 days/wk). Repeated cognitive and EEG assessment will help determine changes in brain function.
- are 60 years of age and over
- have received a diagnosis of mild cognitive impairment
- are English speaking
- have a minimum of high school education
- have adequate hearing and vision
- can identify 15 English vocal/lyrical songs that are associated to your personal memories
- can commit to listening to your personal playlist (20 mins) at-home for 2 weeks (minimum 5 days/week)
The aim of our study is to better understand whether certain lifestyle factors (such as physical activity and hearing) are related to early changes in memory and thinking abilities in older adults. We are especially interested in enrolling individuals who are South Asian or East Asian, because little research has focused on brain health in Canadians of diverse racial/ethnic backgrounds.
By participating, you will help us better understand how lifestyle factors are related to memory and thinking changes in adults from diverse communities. We hope that this will lead to improved prevention and early intervention strategies for dementia.
You are eligible to participate if you…
- Are 55-85 years old
- Have no major medical or psychiatric diagnoses
- Are comfortable speaking and reading English
- Are able to undergo an MRI scan
-Speak English
Eligibility is dependent on an additional conversation with the study team.
VRx@Home is a 5-week virtual reality at-home intervention with the goal to explore whether virtual reality experiences can enhance communication between persons living with dementia and their care partners. We also aim to explore how a head-mounted VR system, which delivers a fully immersive experience compares to a Tablet-based technology.
The study is aiming to assess whether nutritional intervention with personalized, preselected prebiotics can affect cognitive function in those with Alzheimer’s disease. This study is placebo-controlled, and participants will be randomized to either the placebo or prebiotic.
Follow us: